Form 4: Enliven Therapeutics Chief Scientific Officer Exercises Options and Sells Shares

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 11, 2024, Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, exercised options to purchase 30,000 shares of common stock at a price of $1.12 per share.
• Simultaneously, Lyssikatos sold 30,000 shares of common stock at a weighted average price of $25.0444 per share, with individual sales ranging from $25.00 to $25.67.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Lyssikatos directly owns no shares and indirectly owns 1,117,035 shares through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.
• He also holds options for 230,550 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions were part of a pre-planned trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Insider transactions are common, and the use of a 10b5-1 plan suggests the transactions were pre-planned and not based on inside information. Investors often monitor insider activity for signals about a company's prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature mitigates concerns about insider information.

Key Dates